EP1713796A1 - Verfahren zur herstellung substituierter benzopyranverbindungen - Google Patents
Verfahren zur herstellung substituierter benzopyranverbindungenInfo
- Publication number
- EP1713796A1 EP1713796A1 EP05726439A EP05726439A EP1713796A1 EP 1713796 A1 EP1713796 A1 EP 1713796A1 EP 05726439 A EP05726439 A EP 05726439A EP 05726439 A EP05726439 A EP 05726439A EP 1713796 A1 EP1713796 A1 EP 1713796A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- group
- compound
- following formula
- solvates
- salts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Definitions
- the present invention relates to a novel method of preparing substituted benzopyran compounds of the following formula 1, their corresponding novel intermediates and a method of their preparation thereof.
- a benzopyran compound is a leukotriene-receptor antagonist already disclosed in EP 0173516 and others, which is also known as a therapeutic agent for treating diseases induced by leukotriene and 5- ⁇ -reductase.
- JP Hei 3- 95144 discloses a method of preparing 3-amino-2-hydroxyacetophenone from the phenol compound of the following formula (A) via a four step process.
- this method is not considered efficient due to its rather long process and also it lacks industrial applicability due to the risk of explosion during a hydrogenation reaction using Pd/C in the reduction step (a) for introducing an amino group.
- X indicates a halogen atom.
- This invention relates to a method of synthesizing a few novel benzopyran compounds disclosed in EP 0173516.
- the method of the present invention is industrially more applicable since it provides an added safety and efficiency with a fewer number of steps in process as compared to the conventional methods.
- the method of this invention follows the convergent pathway, a more efficient process than the conventional linear process.
- the method of the present invention does not employ a risky process such as hydrogenation reaction and the intermediate materials produced during the reaction are so stable that their separation and purification are quite easy.
- This invention relates to a method of preparing substituted benzopyran compounds having the chemical structure of the following formula 1, a novel intermediate compound used for the process thereof, and a method of preparing the intermediate compound.
- R 1 is selected from the group consisting of a Q-2o alkyl group, a C2-20 alkenyl group, a C2-20 alkynyl group, a phenyl group, a naphthalenyl group and an indanyl group, wherein the groups can be independently substituted by 1 or 2 substituents selected from a C ⁇ -2 o alkyl group, a C 2-2 o alkenyl group and a C 2-2 o alkynyl group, wherein up to 5 carbon atoms of the substitution groups can be selectively substituted by O, S, N, a halogen atom, a benzene ring, a thiophene ring, a naphthalene ring, a C4-7 carbocyclic ring, a carbonyl group, a carbonyloxy group, a hydroxyl group, a carboxy group, an azido group or a nitro group; R 2 and R 4 are independently
- R 1 is a phenyl group or a substituted phenyl group, wherein the above substituted phenyl group can be substituted with 1 or 2 substituents selected from a C1-20 alkyl group, a C2-20 alkenyl group and a C2-20 alkynyl group, wherein up to 5 carbon atoms of the substitution groups can be selectively substituted by O, S, N, a halogen atom, a benzene ring, a thiophene ring, a naphthalene ring, a C -7 carbocyclic ring, a carbonyl group, a carbonyloxy group, a hydroxyl group, a carboxy group, an azido group or a nitro group.
- R 1 is a phenyl group substituted at p-position with a substituent from those exemplified above, and more preferably
- R 2 and R 4 are independently H, a Ci-6 alkyl group, a C2-6 alkenyl group, a Ci-6 alkyl group substituted with from 1 to 3 aryl groups, or a Ci-6 alkoxycarbonyl group. More preferably, R 2 and R 4 are independently H.
- R 3 is H. In preparing the substituted benzopyran compounds of the above formula 1,
- A is a single bond; or a methylene, ethylene, trimethylene, tetramethylene, vinylene, propenylene, butenylene, butadienylene or ethynylene group either substituted or unsubstituted with from 1 to 3 substituents selected from a C ⁇ -10 alkyl group and a phenyl group. More preferably, A is a single bond.
- the substituted benzopyran compounds of the above formula 1 according to the present invention can be prepared by reacting a compound of the following formula 2 with a compound of the following formula 3 as shown in the following reaction scheme 1.
- reaction Scheme 1 In the above reaction scheme 1, R 1 , R 2 , R 3 , R 4 , A, X and Y are the same as defined in the above formula 1.
- the above preparation method according to the reaction scheme 1 is performed at reflux temperature using an organic solvent in the presence of a Pd or Cu catalyst, a ligand and a base.
- the solvent used in the above reaction can be selected from those having high polarity such as ⁇ N'-dimethylformamide, N-methylpyrolidone, pyridine, 1,4- dioxane, C ⁇ -6 alkanol(methanol, ethanol, f-butanol) or a mixture thereof, and preferably N ⁇ N'-dimethylformamide.
- the catalyst used in the above reaction is a Pd- or Cu-containing compound and is used in the range of about 0.1 to 100 mol% with reference to the amomnt of reactants.
- the catalyst is selected from the group consisting of Cul, CuCl, and Q12O, and more preferably Cul.
- the ligand in the above reaction is used in the range of about 0.5 to 3 equivalents with reference to the amount of the catalyst being used.
- the ligand used is diamines or phosphines, preferably the one selected from the group consisting of N,N'-dimethylethylenediamine, trans-N,N'-l,2-cyclohexanediamine and trans-iV,N'- dimethyl-l,2-cyclohexanediamine, and more preferably JSf,N'- dimethylethylenediamine.
- the base in the above reaction is used in the range of about 1 to 10 equivalents with reference to the substrate material.
- the base can be selected from the group consisting of alkali metal alkoxide such as potassium .r-butoxide, potassium methoxide, and sodium methoxide; hydrides such as sodium hydride and potassium hydride; alkali metal carbonate such as potassium carbonate, cesium carbonate, and sodium carbonate; or an alkali metal phosphate such as potassium phosphate and sodium phosphate; and preferably an alkali metal phosphate.
- alkali metal alkoxide such as potassium .r-butoxide, potassium methoxide, and sodium methoxide
- hydrides such as sodium hydride and potassium hydride
- alkali metal carbonate such as potassium carbonate, cesium carbonate, and sodium carbonate
- an alkali metal phosphate such as potassium phosphate and sodium phosphate
- an alkali metal phosphate such as potassium phosphate and sodium phosphate
- the substituted benzopyran compounds of the following formula la, its salts or its solvates are synthesized by reacting a compound of the following formula 2a with a compound of the following formula 3a, its salts or its solvates (e.g., hydrates).
- the reaction is performed while stirring at about 70 to about 100°C for more than a day using ,N'-dimethylformamide as a solvent in the presence of Cul as a catalyst, N,N'-dimethylethylenedia ine as a ligand, and potassium phosphate as a base.
- the reactants i.e., the compound of the above formula 2 (especially the compound of the above formula 2a) and the compound of the above formula 3 (especially the compound of the above formula 3a), are novel intermediate compounds used in synthesizing the compound of the above formula 1. Therefore, the compounds of the above formulas 2 and 3 also belong to the scope of the present invention.
- the compound of the above formula 2 being a novel intermediate compound according to the present invention, can be synthesized by hydrolysis of the compound of the following formula 4 as shown in the following reaction scheme 2.
- reaction Scheme 2 (4) H ( 2)
- R 1 , R 2 , A and Y are the same as defined in the above formula 1.
- an amide group is introduced via hydrolysis using a base in the presence of water, an organic solvent or their mixture. The conditions for a base/ solvent used in the above hydrolysis will be apparent to those skilled in the art.
- the reaction is performed using a single Ci-6 alkanol solvent such as methanol, ethanol, t-butanol or their mixture as a solvent while using alkali hydroxide such as sodium hydroxide or potassium hydroxide as a base.
- alkali hydroxide such as sodium hydroxide or potassium hydroxide as a base.
- the compounds of the following formula 2a, its salts or its solvates are synthesized by reacting the compound of the following formula 4a in the presence of NaOH/f-butanol.
- the compound of the following formula 3 being a novel intermediate compound of the present invention, can be prepared by (a) synthesizing the compound of the following formula 7 by reacting the compound of the following formula 5 with the compound of the following formula 6, and then (b) performing cyclization reaction of thus obtained compound of the following formula 7, as shown in the following reaction scheme 3.
- R 3 , R 4 and X are the same as defined in the above formula 1 and Z indicates an activated leaving group.
- the activated leaving group (Z) of the above reaction scheme 3 are, for example, a halogen atom, an activated amide group represented by - N(R 6 )(OR 6 ) (wherein R 6 is a C ⁇ -6 alkyl group), R 7 0-, R 7 S- or R 7 S0 2 0- (wherein R 7 is a Ci-6 alkyl group, an arbitrarily substituted phenyl group or an arbitrarily substituted phenyl Ci-6 alkyl group), or
- R 8 is a Ci-6 alkyl group, an arbitrarily substituted phenyl group or an arbitrarily substituted phenyl C 1-6 alkyl group, Y's are independently O or S).
- the activated leaving group is R 7 0-, wherein R 7 is a Ci- ⁇ alkyl group, an arbitrarily substituted phenyl group or an arbitrarily substituted phenyl Ci-6 alkyl group, more preferably, R 7 is a Ci- ⁇ alkyl group, for example, a methyl group, an ethyl group, z— butyl group or t-butyl group, and most preferably R 7 is an ethyl group.
- the step (a) of the synthesis according to the above reaction scheme 3 is performed in the presence of N,N'-dimethylformamide, an ether solvent such as tetrahydrofuran; an organic solvent such as toluene, benzene, hexane or a C ⁇ -6 alkanol (e.g., methanol, ethanol, t-butanol); and a base, wherein the base can be selected from the group consisting of alkali metal alkoxide such as potassium t- butoxide, potassium methoxide, and sodium methoxide; hydrides such as sodium hydride; and amides such as potassium amide and sodium amide.
- an ether solvent such as tetrahydrofuran
- an organic solvent such as toluene, benzene, hexane or a C ⁇ -6 alkanol (e.g., methanol, ethanol, t-butanol)
- a base wherein the base
- the cyclization in step (b) of the synthesis according to the above reaction scheme 3 is performed in the presence of an acid.
- the cyclization can be performed in the presence of a sulfuric acid using a solvent such as Ci-e alkanol or acetic acid.
- the cyclization can be performed in the presence of hydrochloric acid in the mixed solvent of Ci-6 alkanol/ tetrahydrofuran.
- Alternative acid/ solvent conditions will be apparent to those skilled in the art.
- the reaction can be performed in a suitable solvent such as water or Ci-6 alkanol, unsaturated carbocyclic hydrocarbon such as benzene or toluene, by using an acid such as hydrobromic acid, hydroiodic acid, perchloric acid or p-toluenesulfonic acid; and a Lewis acid such as aluminum trichloride or titanium, tetrachloride.
- a suitable solvent such as water or Ci-6 alkanol, unsaturated carbocyclic hydrocarbon such as benzene or toluene
- an acid such as hydrobromic acid, hydroiodic acid, perchloric acid or p-toluenesulfonic acid
- a Lewis acid such as aluminum trichloride or titanium, tetrachloride.
- the above reaction is performed in methanol solvent in the presence of sulfuric acid.
- the compounds of the following formula 3a, its salts or its solvates are prepared by (a) synthesizing the compound of the following formula 7a, its salts and its solvates (e.g., hydrides) by reacting the compound of the following formula 5a with the compound of the following formula 6a, its salts and its solvates (e.g., hydrides) and then (b) performing the cyclization reaction of the compound of the following formula 7a, its salts and its solvates.
- the compound of the above formula 7 (especially the compound of the above formula 7a) is a novel intermediate compound synthesized during the reaction. Therefore, the compound of the above formula 7 also belongs to the scope of the present invention.
- the compound of the above formula 7 is indicated as di-keto type in this invention for convenience, but it can be also present in the form of keto-enol and cyclic hydroxy chromanone. Therefore, all of the tautomeric forms of the above formula 7 belong to the scope of this invention.
- Example 1 Preparation of 4- (4-phenylbutoxy)benzamide To a mixture of 4-(4-phenylbutoxy)benzonitrile (1.9 g, 7.5 mmol) and t- butanol (37 mL) was added NaOH (2.1 g, 38 mmol) and refluxed for 4 hours. The mixture was cooled to room temperature and then added to a mixed solution of water and methanol (4 : 1, 100 mL). The resulting precipitate was filtered, washed with water and then dried under vacuum to give the target compound as a white solid (1.9 g, 94%).
- the mixture was cooled to room temperature and then slowly added to cold IN HC1 (120 mL).
- the resulting orange precipitate was filtered, washed with water and then dried under vacuum to obtain the target compound.
- the target compound was dissolved in ethylacetate by applying heat, added with hexane and then placed at 0 °C for 2 hours.
- the resulting product was filtered, washed with hexane and then dried under vacuum to give the purified product as a yellow solid(1.7 g, 83%).
- Example 3 Preparation of 8-iodo-4-oxo-2-tetrazol-5-yl-lH-l-benzopyran
- the purified product obtained in Example 2(1.5 g, 4.2 mmol) was mixed in methanol(20 mL) and stirred to produce a slurry.
- the slurry was then added with a cone, sulfuric acid (265 ⁇ L, 5.0 mmol) and refluxed for 7 hours.
- the mixture was cooled to room temperature and then maintained at 0 °C for an hour.
- the resulting product was filtered, washed with cold methanol, water and cold methanol.
- the resulting product was dried under vacuum to afford the target compound as a pale yellow solid(1.3 g, 93%).
- Example 4 Preparation of 4-oxo-8-[4-(4-ph.enylbutoxy)benzoylamino]-2-tetrazol-5- yl-4H-l-benzopyran Under the nitrogen atmosphere, the purified product obtained in Example 1 (108 mg, 0.40 mmol), the purified product obtained in Example 3 (68 mg, 0.20 mmol), Cul (11.4 mg, 0.04 mmol), potassium phosphate (255 mg, 0.80 mmol) and N,N'- dimemylethylenediamine (13 ⁇ L, 0.08 mmol) were mixed together. The mixture was then added with anhydrous dimethylforrriamide (1 mL) and stirred at 100 °C for two days.
- the reaction solution was cooled to room temperature and added with water(15 mL).
- the resulting solution was acidified to pHl-2 by adding a saturated HC1 solution.
- the precipitated solid was filtered and the resulting solid was suspended in methanol(lOmL) and then filtered to remove the remaining purified product obtained in Example 1.
- the obtained solid was dissolved in methanol (7mL) by adding sodium acetate (32 mg, 0.40 mmol) and then filtered.
- the filtrate was added with saturated HC1 solution.
- the precipitated solid was filtered, washed with cold methanol and then dried under vacuum to obtain the target compound as a pale yellow solid(77 mg, 81%).
- the present invention relates to a manufacturing process suitable for industrial application, which provides a much improved and more efficient method with secured safety as compared to the conventional methods.
- the compounds represented in the above formulas 2, 3 and 7 are novel intermediate compounds produced in the course of synthesizing substituted benzopyran compounds of the formula 1, and they will also be very useful in industrial application due to their great stability.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020040009280A KR100683274B1 (ko) | 2004-02-12 | 2004-02-12 | 치환된 벤조피란 화합물의 제조방법 |
PCT/KR2005/000365 WO2005077942A1 (en) | 2004-02-12 | 2005-02-07 | Process for preparing substituted benzopyran compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1713796A1 true EP1713796A1 (de) | 2006-10-25 |
EP1713796A4 EP1713796A4 (de) | 2009-11-25 |
Family
ID=34858705
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP05726439A Withdrawn EP1713796A4 (de) | 2004-02-12 | 2005-02-07 | Verfahren zur herstellung substituierter benzopyranverbindungen |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1713796A4 (de) |
JP (1) | JP4512100B2 (de) |
KR (1) | KR100683274B1 (de) |
CN (1) | CN1918150B (de) |
WO (1) | WO2005077942A1 (de) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009147682A1 (en) | 2008-06-05 | 2009-12-10 | Novotyr Therapeutics Ltd. | Novel modulators of protein kinase signaling |
EP3021944B1 (de) | 2013-07-14 | 2018-12-19 | Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. | Igf-1r signalweginhibitoren zur behandlung von neurodegenerativen erkrankungen |
EP3253733B1 (de) | 2015-02-05 | 2020-04-29 | TyrNovo Ltd. | Kombinationen von irs/stat3-doppelmodulatoren und antikrebsmittel zur behandlung von krebs |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0173516A2 (de) * | 1984-08-20 | 1986-03-05 | Ono Pharmaceutical Co., Ltd. | (Kondensierte) Benz(thio)amide |
US5623082A (en) * | 1988-05-03 | 1997-04-22 | Basf Aktiengesellschaft | Preparation of acyl chlorides |
EP1178040A1 (de) * | 1996-07-01 | 2002-02-06 | E.I. Du Pont De Nemours And Company | Nickel-katalysierte Addition von -NH- enthaltende Verbindungen und Vinyl- und Aryl-Halogeniden |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US389339A (en) * | 1888-09-11 | Friction-clutch | ||
GB1296469A (de) | 1970-02-05 | 1972-11-15 | ||
CA960223A (en) * | 1970-02-05 | 1974-12-31 | Mervyn E. Peel | Tetrazolyl chromones |
US4238495A (en) * | 1976-01-30 | 1980-12-09 | Miles Laboratories, Inc. | 1-(4-Cyano-phenoxy)-2-hydroxy-3-[2-(5-1H-tetrazolyl)-chromon-5-yloxy]-propane and salts thereof |
US4158663A (en) * | 1977-07-15 | 1979-06-19 | Warner-Lambert Company | Process for the production of 2-substituted chromones |
JPS60246384A (ja) * | 1984-05-21 | 1985-12-06 | Hokuriku Seiyaku Co Ltd | クロモン−8−カルポキサミド誘導体 |
JPH0395144A (ja) * | 1989-08-04 | 1991-04-19 | Ono Pharmaceut Co Ltd | アミノフェノール誘導体の製造方法 |
JPH051008A (ja) * | 1991-06-19 | 1993-01-08 | Mitsubishi Kasei Corp | 1,4−ジシアノブテン類の製造法 |
GB9224922D0 (en) | 1992-11-27 | 1993-01-13 | Smithkline Beecham Plc | Process |
US5597929A (en) | 1994-06-23 | 1997-01-28 | Sumitomo Chemical Co., Ltd. | Production process of 2-(tetrazol-5-yl)-4-oxo-4H-benzopyran |
CH691301A5 (de) * | 1995-06-29 | 2001-06-29 | Sumitomo Chemical Co | Verfahren zur Herstellung von 2-Acetyl-6-(4-(4-phenylbutoxy)benzoyl)aminophenol. |
AR004029A1 (es) * | 1995-10-20 | 1998-09-30 | Smithkline Beecham Plc | Nuevas formulaciones farmaceuticas |
JPH09323955A (ja) * | 1996-06-03 | 1997-12-16 | Kao Corp | 安息香酸誘導体及びこれを含有する医薬 |
GB9700331D0 (en) | 1997-01-09 | 1997-02-26 | Smithkline Beecham Plc | Process |
PT1260511E (pt) * | 1997-05-09 | 2005-05-31 | Lundbeck & Co As H | Processo para a preparacao de 5-cloro-1-(4-fluorofenil)-3-(1,2,3,6-tetra-hidropiridin-4-il) indole e metodo para a producao de sertindole |
CN1863752A (zh) * | 2002-08-02 | 2006-11-15 | 罗迪亚药业公司 | 铜催化的芳基化 |
-
2004
- 2004-02-12 KR KR1020040009280A patent/KR100683274B1/ko not_active IP Right Cessation
-
2005
- 2005-02-07 CN CN2005800047261A patent/CN1918150B/zh not_active Expired - Fee Related
- 2005-02-07 EP EP05726439A patent/EP1713796A4/de not_active Withdrawn
- 2005-02-07 WO PCT/KR2005/000365 patent/WO2005077942A1/en active Application Filing
- 2005-02-07 JP JP2006553050A patent/JP4512100B2/ja not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0173516A2 (de) * | 1984-08-20 | 1986-03-05 | Ono Pharmaceutical Co., Ltd. | (Kondensierte) Benz(thio)amide |
US5623082A (en) * | 1988-05-03 | 1997-04-22 | Basf Aktiengesellschaft | Preparation of acyl chlorides |
EP1178040A1 (de) * | 1996-07-01 | 2002-02-06 | E.I. Du Pont De Nemours And Company | Nickel-katalysierte Addition von -NH- enthaltende Verbindungen und Vinyl- und Aryl-Halogeniden |
Non-Patent Citations (1)
Title |
---|
See also references of WO2005077942A1 * |
Also Published As
Publication number | Publication date |
---|---|
JP4512100B2 (ja) | 2010-07-28 |
KR100683274B1 (ko) | 2007-02-15 |
JP2007522206A (ja) | 2007-08-09 |
WO2005077942A1 (en) | 2005-08-25 |
CN1918150B (zh) | 2010-05-05 |
KR20050081042A (ko) | 2005-08-18 |
CN1918150A (zh) | 2007-02-21 |
EP1713796A4 (de) | 2009-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6061158B2 (ja) | 6−(7−((1−アミノシクロプロピル)メトキシ)−6−メトキシキノリン−4−イルオキシ)−n−メチル−1−ナフトアミド、またはそれの薬学的に許容される塩の合成中間体およびその使用 | |
US20050288350A1 (en) | Bicyclic androgen and progesterone receptor modulator compounds and methods | |
JP3763828B2 (ja) | ベンゾピラン化合物の前駆体合成のための中間体の製造方法 | |
CA2786434C (en) | Method for preparing tetrazole methanesulfonic acid salts, and novel compound used in same | |
CZ20023665A3 (cs) | Zkrácená syntéza derivátů 3,3-diarylpropylaminu | |
WO2005077942A1 (en) | Process for preparing substituted benzopyran compounds | |
WO2005070909A1 (en) | An improved process for the preparation of gefitinib | |
JP4656604B2 (ja) | イノシン誘導体及びその製造方法 | |
US8093384B2 (en) | Processes for the preparation of alfuzosin | |
KR20090105309A (ko) | 광학활성을 갖는 5-히드록시-3-옥소헵타노에이트 유도체의제조방법 | |
KR100760015B1 (ko) | 벤조피란 화합물 합성용 중간체 | |
KR100716274B1 (ko) | 치환된 벤조피란 화합물 합성용 화합물 | |
KR100740325B1 (ko) | 치환된 벤조피란 화합물 합성용 화합물 | |
CN113336703A (zh) | 1,3,4,5-四取代1h-吡唑衍生物的合成 | |
US6114549A (en) | Process of making 3-phenyl-1-methylenedioxyphenyl-indane-2-carboxylic acid derivatives | |
KR100739439B1 (ko) | 8-아미노-4-옥소-2-(테트라졸-5-일)-4에이치-1-벤조피란 또는 그의 염의 제조방법 및 그의 제조용 중간체 | |
JP2537682B2 (ja) | 3―アリ―ルオキシカテコ―ル類の製造方法 | |
JPH10500421A (ja) | ベンゾピラン化合物の製造方法 | |
EP4182294A1 (de) | Verfahren und zwischenprodukte zur herstellung von menachinon mk-7 | |
WO2000029369A1 (fr) | Derives d'acide aminoacrylique et procede de production correspondant | |
JP2002338570A (ja) | 3−アミノ−1,8−ナフチリジン−2(1h)−オン誘導体の製造法 | |
KR20050036409A (ko) | 카바졸온 유도체 제조 방법 | |
JPH0782267A (ja) | 1,4−ベンゾオキサジン誘導体 | |
KR20080113160A (ko) | 8-아미노-4-옥소-2-(테트라졸-5-일)-4h-1-벤조피란 및이를 통한 프란누카스트의 제조 방법 | |
JP2013224334A (ja) | ドデカヒドロ−ナフト−フラニル−カルバミン酸エステル中間体調製のための高純度合成プロセス |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20060825 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): IT TR |
|
DAX | Request for extension of the european patent (deleted) | ||
RBV | Designated contracting states (corrected) |
Designated state(s): IT TR |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20091028 |
|
17Q | First examination report despatched |
Effective date: 20100420 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20121127 |